YuKC, NettarKD, BapnaS, BoscardinWJ, MaasCS. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.. Arch Facial Plast Surg. 2012; 14(3):198–204 22183059
2.
NettarKD, YuKC, BapnaS, BoscardinJ, MaasCS. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.. Arch Facial Plast Surg. 2011; 13(6):380–386 21690460
3.
HambletonP, PickettAM. Potency equivalence of botulinum toxin preparations.. J R Soc Med. 1994; 87(11):719 7837204
AscherB, RzanyBJ, GroverR. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.. Dermatol Surg. 2009; 35(10):1478–1486 19686365
6.
MonheitG, CarruthersA, BrandtF, RandR. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.. Dermatol Surg. 2007; 33(1, theme issue.):S51–S59 17241415
WohlfarthK, SychaT, RanouxD, NaverH, CairdD. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?. Curr Med Res Opin. 2009; 25(7):1573–1584 19463043
9.
KarsaiS, RaulinC. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology.. Dermatol Surg. 2009; 35(1):1–8 19018816
